Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Gefitinib products are in shortage in Canada (1 of 4 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Dec 31, 2026.
A targeted therapy used to treat certain types of non-small cell lung cancer.
Products affected
1 / 4
In shortage since
Apr 4, 2025
Est. full return
Dec 31, 2026
Reports on file
5
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
NAT-GEFITINIB
250MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02491796 · since Apr 4, 2025, est. end Dec 31, 2026 · Long Term Back Order
Discontinued
SANDOZ GEFITINIB
250MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02487748
Resolved
SANDOZ GEFITINIB
250MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02487748 · ended Nov 3, 2025 · Disruption of the manufacture of the drug.
Resolved
JAMP GEFITINIB
250MG · TABLET · JAMP PHARMA CORPORATION
DIN 02500663 · ended Jan 31, 2024 · Disruption of the manufacture of the drug.
Resolved
APO-GEFITINIB
250MG · TABLET · APOTEX INC
DIN 02468050 · ended Jun 23, 2022 · Disruption of the manufacture of the drug.
What's happening
Gefitinib is currently affected by an active shortage report filed with Health Canada by NATCO PHARMA (CANADA) INC.
The reported cause is: long term back order. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Recent changes
No changes recorded yet.
Common questions
What is Gefitinib used for?
A targeted therapy used to treat certain types of non-small cell lung cancer.
When will Gefitinib be back in stock in Canada?
The latest manufacturer estimate is Dec 31, 2026. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Gefitinib in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Possible alternatives in the same class
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.